180 related articles for article (PubMed ID: 17635670)
1. Minocycline and riluzole brain disposition: interactions with p-glycoprotein at the blood-brain barrier.
Milane A; Fernandez C; Vautier S; Bensimon G; Meininger V; Farinotti R
J Neurochem; 2007 Oct; 103(1):164-73. PubMed ID: 17635670
[TBL] [Abstract][Full Text] [Related]
2. Interactions between antiparkinsonian drugs and ABCB1/P-glycoprotein at the blood-brain barrier in a rat brain endothelial cell model.
Vautier S; Milane A; Fernandez C; Buyse M; Chacun H; Farinotti R
Neurosci Lett; 2008 Sep; 442(1):19-23. PubMed ID: 18598736
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception.
Kalvass JC; Olson ER; Pollack GM
Drug Metab Dispos; 2007 Mar; 35(3):455-9. PubMed ID: 17178769
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists.
Smith BJ; Doran AC; McLean S; Tingley FD; O'Neill BT; Kajiji SM
J Pharmacol Exp Ther; 2001 Sep; 298(3):1252-9. PubMed ID: 11504828
[TBL] [Abstract][Full Text] [Related]
5. Brain and plasma riluzole pharmacokinetics: effect of minocycline combination.
Milane A; Tortolano L; Fernandez C; Bensimon G; Meininger V; Farinotti R
J Pharm Pharm Sci; 2009; 12(2):209-17. PubMed ID: 19732498
[TBL] [Abstract][Full Text] [Related]
6. Regional differences in capillary density, perfusion rate, and P-glycoprotein activity: a quantitative analysis of regional drug exposure in the brain.
Zhao R; Pollack GM
Biochem Pharmacol; 2009 Oct; 78(8):1052-9. PubMed ID: 19523457
[TBL] [Abstract][Full Text] [Related]
7. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin.
Zong J; Pollack GM
J Pharmacol Exp Ther; 2003 Aug; 306(2):556-62. PubMed ID: 12721332
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.
Schinkel AH; Wagenaar E; Mol CA; van Deemter L
J Clin Invest; 1996 Jun; 97(11):2517-24. PubMed ID: 8647944
[TBL] [Abstract][Full Text] [Related]
9. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography.
Hendrikse NH; Schinkel AH; de Vries EG; Fluks E; Van der Graaf WT; Willemsen AT; Vaalburg W; Franssen EJ
Br J Pharmacol; 1998 Aug; 124(7):1413-8. PubMed ID: 9723952
[TBL] [Abstract][Full Text] [Related]
10. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats.
Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T
Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062
[TBL] [Abstract][Full Text] [Related]
11. Disposition of Delta tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein.
Bonhomme-Faivre L; Benyamina A; Reynaud M; Farinotti R; Abbara C
Addict Biol; 2008 Sep; 13(3-4):295-300. PubMed ID: 18331373
[TBL] [Abstract][Full Text] [Related]
12. Lack of difference in pulmonary absorption of digoxin, a P-glycoprotein substrate, in mdr1a-deficient and mdr1a-competent mice.
Manford F; Riffo-Vasquez Y; Spina D; Page CP; Hutt AJ; Moore V; Johansson F; Forbes B
J Pharm Pharmacol; 2008 Oct; 60(10):1305-10. PubMed ID: 18812023
[TBL] [Abstract][Full Text] [Related]
13. Increased P-glycoprotein function and level after long-term exposure of four antiepileptic drugs to rat brain microvascular endothelial cells in vitro.
Yang HW; Liu HY; Liu X; Zhang DM; Liu YC; Liu XD; Wang GJ; Xie L
Neurosci Lett; 2008 Apr; 434(3):299-303. PubMed ID: 18313849
[TBL] [Abstract][Full Text] [Related]
14. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier.
Dirson G; Fernandez C; Hindlet P; Roux F; German-Fattal M; Gimenez F; Farinotti R
Pharm Res; 2006 Jul; 23(7):1525-32. PubMed ID: 16779703
[TBL] [Abstract][Full Text] [Related]
15. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein.
Gnoth MJ; Sandmann S; Engel K; Radtke M
Drug Metab Dispos; 2010 Aug; 38(8):1341-6. PubMed ID: 20413726
[TBL] [Abstract][Full Text] [Related]
16. Altered disposition and antinociception of [D-penicillamine(2,5)] enkephalin in mdr1a-gene-deficient mice.
Chen C; Pollack GM
J Pharmacol Exp Ther; 1998 Nov; 287(2):545-52. PubMed ID: 9808679
[TBL] [Abstract][Full Text] [Related]
17. A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs.
Linnet K; Ejsing TB
Eur Neuropsychopharmacol; 2008 Mar; 18(3):157-69. PubMed ID: 17683917
[TBL] [Abstract][Full Text] [Related]
18. Efflux transport of a new quinolone antibacterial agent, HSR-903, across the blood-brain barrier.
Murata M; Tamai I; Kato H; Nagata O; Tsuji A
J Pharmacol Exp Ther; 1999 Jul; 290(1):51-7. PubMed ID: 10381759
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline.
Grauer MT; Uhr M
J Psychopharmacol; 2004 Mar; 18(1):66-74. PubMed ID: 15107187
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein-mediated efflux of phenobarbital at the blood-brain barrier evidence from transport experiments in vitro.
Yang ZH; Liu XD
Epilepsy Res; 2008 Jan; 78(1):40-9. PubMed ID: 18063342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
